Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
64
resultados
Última actualización
31/08/2025 [07:19:00]
Resultados 25 a 50 de 64
Resumen de: US2025251407A1
A monoclonal antibody composition comprises a capture antibody AB7G and a detection antibody AB11A2 for using in preparation of a kit for quantitative detection of amyloid in human body fluids, and the antibodies are monoclonal antibodies secreted by cultured hybridoma cells. The kit specifically recognizes an Aβ42 oligomer, with a linear detection range of 3.9-125 pg/mL, and a lowest detection limit of 7.8 pg/mL. A core technique for kit assembly lies in that the monoclonal antibody AB7G is fixed on a microplate to serve as the capture antibody, and the monoclonal antibody AB11A2 is labeled and then diluted at 1:2000 to serve as the detection antibody. Meanwhile, the present invention relates to heavy and light chain variable region genes of the monoclonal antibodies AB7G and AB11A2 and peptides encoded thereby.
Resumen de: WO2024069193A1
The invention relates to methods of screening for the presence of proteopathies, to methods of diagnosing proteopathies, to methods of differentially diagnosing proteopathies, to methods of assessing the severity, stage and/or prognosis of proteopathies, and to methods for monitoring the progression of proteopathies. The invention also relates to methods for determining the efficacy of therapeutic interventions for proteopathies.
Resumen de: EP4597103A1
The objective of the present invention is to provide a method for screening for a substance having activity of inhibiting or promoting aggregation of aggregating proteins. More specifically, the present invention relates to a method for evaluating activity of a test substance for inhibiting or promoting aggregation of aggregating proteins comprising: a step of culturing cells in the presence of aggregating proteins labeled with a label and a test substance; and a step of quantifying the aggregated and/or deposited aggregating proteins on the cell surface and/or in the cells in the cell culture product with the use of the label as the indicator.
Resumen de: AU2023351193A1
Provided herein are methods and compositions that block Integrin Subunit beta 8 (ITGB8, also known as integrin αvβ8) to treat neurodegenerative diseases associated with microglial impairment including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS).
Resumen de: WO2024014834A1
The present invention relates to a biomarker for the early diagnosis of Alzheimer's disease and a use thereof, and more particularly, the present invention relates to: a biomarker composition for the early diagnosis of Alzheimer's disease, the biomarker composition comprising one or more genes selected from the group consisting of alpha-2-macroglobulin (A2M), creatine kinase M-type (CKM), filamin-A (FLNA), integral alpha-IIb (ITGA2B), alpha-1-acid glycoprotein 2 (ORM2), phospholipid transfer protein (PLTP), haptoglobin (HP), sulfhydryl oxidase 1 (QSOX1), protein-glutamine gamma-glutamyltransferase 2 (TGM2), filamin C (FLNC), heat shock protein 70 (HSP70) and lysomal alpha-mannosidase (heat shock protein MAN2B1), or a protein expressed from the genes; a method for the early diagnosis of Alzheimer's disease; a diagnostic kit for the early diagnosis of Alzheimer's disease; and a method for providing information for predicting and diagnosing Alzheimer's disease.
Resumen de: MX2025008034A
The present disclosure provides anti-amyloid β (Aβ) antibodies and antibody fragments that preferentially bind soluble amyloid Aβ protofibril/oligomer and trigger ADPC in microglial cells, anti-amyloid β (Aβ) antibodies and antibody fragments that reduce soluble amyloid Aβ protofibril/oligomer levels and insoluble amyloid Aβ plaque in brain tissue, and the use of anti-Aβ protofibril/oligomer antibodies and antibody fragments in therapy, prophylaxis, diagnosis, screening, and monitoring of conditions associated with Aβ protein aggregation, in particular Alzheimer's disease (AD).
Resumen de: WO2025159608A1
The present invention relates to the identification of a target material through which Porphyromonas gingivalis affects dementia, and a use of a Porphyromonas gingivalis vaccine for preventing or treating dementia. A composition comprising (Porphyromonas gingivalis, of the present invention, reduces the expression of IGFBP2, Aß and p-Tau and reduces the level of blood insulin, and thus can be used as an effective composition for a dementia vaccine or a composition for preventing, alleviating or treating dementia, and can be effectively used in a method for preventing or treating dementia.
Resumen de: US2025244342A1
The disclosure relates to methods and kits for detecting tau, e.g., tau that is phosphorylated at amino acid position T181 (pTau181), tau that is phosphorylated at amino acid position T217 (pTau217), and/or total tau. The disclosure further provides methods for distinguishing between individuals whose cognitive condition will remain stable and whose cognitive condition will decline during their lifetime. The disclosure also provides methods for determining the eligibility of individuals for participation in clinical trials for Alzheimer's disease treatments. Also provided are methods for distinguishing between individuals with Alzheimer's disease and non-Alzheimer's dementia, and for monitoring response to treatment for Alzheimer's disease.
Resumen de: EP4592679A1
The present invention discloses use of an agent for detecting the expression level of discoidin domain receptor 2 (DDR2) in the preparation of a kit for diagnosing a neurodegenerative disease in a subject, wherein the level of DDR2 in a sample from the subject being higher than the level of a control not having the disease indicates that the subject has the neurodegenerative disease. The present invention also discloses a kit and a method for diagnosing a neurodegenerative disease, and a computer-readable storage medium. The present invention can efficiently and accurately diagnose the neurodegenerative disease by detecting DDR2.
Resumen de: MX2025003197A
The disclosure relates to lemborexant, a dual orexin receptor antagonist, and compositions and methods for use in treatment of Alzheimer's disease (AD), e.g., in a subject who has AD or who is at risk for developing AD.
Resumen de: MX2025005880A
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain using a tau PET level.
Resumen de: TW202502373A
The invention provides application of IL-27 protein in preparation of a product for treating Alzheimer's disease, and belongs to the technical field of biological medicine. The IL-27 protein is a recombinant IL-27 protein, and aims at a treatment target IL-27, and comprises a mouse source IL-27, a human source IL-27, and a mammal IL-27 except the mouse source IL-27 and the human source IL-27. The recombinant IL-27 protein provided by the invention can effectively relieve Alzheimer's disease caused by A beta deposition, and can be selectively and specifically combined with a receptor of the recombinant IL-27 protein, so that the accuracy of a detection result is ensured; the specificity of the protein receptor is highly expressed in the dentate gyrus region of the sea horse, so that the drug targeting is ensured to the greatest extent; the recombinant IL-27 protein has a good application prospect, can quickly and effectively improve and relieve memory impairment and other behaviors of mice with Alzheimer's disease, and has a clinical transformation value.
Resumen de: KR20250113108A
본 발명은아밀로이드베타 검출을 위한 탄소나노셀룰로오스-팔라듐 나노복합체 제조방법 및 이의 용도에 관한 것으로, 본 발명의 제조방법에 따른 탄소나노셀룰로오스-팔라듐 나노복합체(Pd-CNC)는 아밀로이드베타(Amyloid-β)에 대하여 높은 친화도를 가져 이를 바이오센서로 사용하는 경우 종래의 비색 센서에 비해 적은 시료량을 요구하며, 검출 민감도가 현저히 우수한 효과가 있다. 또한, 종래의 비색 센서와 달리 값비싼 항체를 요구하지 않으며 간단한 장비로 아밀로이드베타를 검출할 수 있어 검출 비용이 저렴하다는 장점이 있다.
Resumen de: WO2025155794A1
The present inventive concept provides a subject's fecal protein bioprofile and methods for establishing the same. Also provided are methods of determining a subject's risk for developing an inflammatory disorder, a neurological disorder, a neurodegenerative disorder, or a disorder associated with aging or monitoring the same. The inventive concept further provides kits for use in the methods described herein.
Resumen de: US2025235464A1
Described herein are methods for inhibiting generation of one or more non-classical variant(s) of amyloid precursor protein (APP) gene. Provided herein are methods for diagnosing an individual having or suspected of having Alzheimer's disease following identification of an expression profile or an activity profile of the one or more non-classical variant(s) and treating the individual using a reverse transcriptase inhibitor or salt thereof.
Resumen de: US2025238922A1
Described are platforms, systems, and methods for screening patients. In one aspect, a computer-implemented method comprises: receiving, from a cellular imaging device, image data comprising calcium kinetic features of neuronal cultures derived from a patient; processing the image data through a machine-learning model to determine a diagnosis for the patient based on the calcium kinetic features, the machine-learning model trained using neuronal calcium data; and providing the diagnosis a user interface.
Resumen de: US2025237652A1
Provided herein are compositions and methods related to the production and detection of a histone H1.0 protein dimethylated at lysine residue 180 (K180) (H1.0K180me2 protein) or a histone H1.0 peptide dimethylated at a lysine residue corresponding to K180 (H1.0K180me2 peptides). The H1.0K180me2 protein and H1.0K180me2 peptides are useful for applications including, but not limited to, molecular diagnostics of DNA damage, genotoxic stress, radiation exposure, and Alzheimer's disease, therapeutics, monitoring of therapeutic regimens, patient stratification, and drug screening. Also provided herein are antibodies specific for the H1.0K180me2 protein and H1.0K180me2 peptides.
Resumen de: EP4589015A2
In vitro method for the diagnosis of synucleinopathies. The present invention is directed to an in vitro method for the specific diagnosis of a synucleinopathy and/or for the differential diagnosis of a synucleinopathy from Alzheimer disease (AD). In a preferred embodiment, the synucleinopathy is Dementia with Lewy bodies (DLB) or Parkinson's disease (PD).
Resumen de: JP2024037794A
To provide a method for measuring an amount of singly or multiply phosphorylated p217+tau protein in a sample, regarding compositions and methods for detecting neurodegeneration.SOLUTION: A method for measuring a p217+ tau peptide in a sample, comprises: (i) contacting the sample with a capture antibody against a p217+ tau epitope to capture the p217+ tau peptide in the sample; and (ii) contacting the captured p217+ tau peptide with at least one of a first detection antibody against an epitope comprising amino acid residues 119 to 126 of a tau protein and a second detection antibody against an epitope comprising amino acid residues 7 to 20 of the tau protein, and measuring at least one of an amount of the p217+ tau peptide and an amount of a long p217+ tau peptide, where amino acid numbering refers to a specific amino acid sequence.SELECTED DRAWING: None
Resumen de: WO2025148411A1
A protein antigen for Alzheimer's disease detection comprises at least any two of DOC2A, LGALS1, KDM4D, and ADARB1 proteins at the same time, can be used for early detection or diagnosis of Alzheimer's disease, and is suitable for risk assessment and prediction of before the onset of Alzheimer's disease; moreover, the protein antigen can distinguish Alzheimer's disease from other types of dementia, and can be further prepared into a related reagent or kit according to requirements.
Resumen de: US2025231178A1
The present disclosure relates to a method for determining a risk of development or risk of presence of Alzheimer's disease in a human subject comprising analyzing an activity of a PIEZO1 receptor. The disclosure also relates to a kit for determining a risk of development or risk of presence of Alzheimer's disease according to the present method. The disclosure also relates to an in vitro use of a PIEZO1 receptor as a biomarker and determination of intracellular calcium level as a biomarker for determining a risk of development or risk of presence of Alzheimer's disease in a human subject.
Resumen de: US2025231201A1
Described herein are biological devices and extracts useful for detecting Alzheimer's disease and/or concussions. The biological devices include microbial cells transformed with a DNA construct containing genes for producing β-amyloid precursor protein, microtubule associated protein tau, adipose triglyceride lipase, acyl-CoA dehydrogenase, and O-linked N-acetylglucosamine transferase. In some instances, the biological devices also include a gene for enhanced green fluorescent protein. Methods for using the devices to diagnose or detect Alzheimer's disease and/or concussions are also provided herein.
Resumen de: AU2025204747A1
The invention relates to methods and compositions for developing basal forebrain cholinergic neurons (BFCNs) from stem cells, and in particular, BFCNs having repaired electrophysiological defects relating to one or more mutations in PSEN2, and to the use of such BFCNs in cell-based therapies to treat Alzheimer’s disease. The invention relates to methods and compositions for developing basal forebrain cholinergic neurons (BFCNs) from stem cells, and in particular, BFCNs having repaired electrophysiological defects relating to one or more mutations in PSEN2, and to the use of such BFCNs in cell-based therapies to treat Alzheimer's disease. un u n h e i n v e n t i o n r e l a t e s t o m e t h o d s a n d c o m p o s i t i o n s f o r d e v e l o p i n g b a s a l f o r e b r a i n c h o l i n e r g i c n e u r o n s ( s ) f r o m s t e m c e l l s , a n d i n p a r t i c u l a r , s h a v i n g r e p a i r e d e l e c t r o p h y s i o l o g i c a l d e f e c t s r e l a t i n g t o o n e o r m o r e m u t a t i o n s i n , a n d t o t h e u s e o f s u c h s i n c e l l - b a s e d t h e r a p i e s t o t r e a t l z h e i m e r ' s d i s e a s e
Resumen de: KR20250109288A
본 발명은 종래의 퇴행성 뇌질환과 관련된 유전인자로 히스톤 탈아세틸화 효소 (Histone deacetylase; HDAC)를 발굴하고 이에 의하여 조절되는 BNIP3 단백질에 의해 신경세포내의 손상된 미토콘드리아를 제거하는 기전이 제어됨을 밝혔으며, 이를 통하여 손상 미토콘드리아의 자가포식과정이 활성화되고 퇴행성 뇌질환의 진행이 억제될 가능성을 보였으므로 HDAC6와 BNIP3 그리고 관련된 p53의 K320 acetylation을 이용하여 퇴행성 뇌질환의 정보제공 또는 치료제 선별 스크리닝에 유용하게 응용할 수 있을 것으로 기대된다.
Nº publicación: EP4584388A1 16/07/2025
Solicitante:
NEURO BIO LTD [GB]
Neuro-Bio Ltd
Resumen de: WO2024052650A1
The invention relates to neurodegenerative disorders, and the diagnosis and/or prognosis of neurodegenerative disorders in a test subject using a lateral flow test, or the like. The invention also relates to detecting diagnostic and prognostic biomarkers in a range of various patient sample types for diagnosing and/or prognosing neurodegenerative disorders, such as Alzheimer's disease. The invention further provides biomarker detection methods, and apparatus and apparatuses for diagnosing and prognosing neurodegenerative disorders, and methods of treating patients diagnosed or prognosed with a neurodegenerative disorder. The invention also extends to detection of biomarkers and/or screening in pre-symptomatic subjects, for early diagnosis, to enable disease prevention or intervention.
BOPI
Sede Electrónica
